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BACKGROUND:When compared with warfarin, edoxaban signiﬁcantly reduced cardiovascular mortality in the
Effective Anticoagulation with Factor Xa Next Generation in Atrial FibrillationeThrombolysis in Myocardial
Infarction 48 (ENGAGE AF-TIMI 48) trial. We studied the possible reasons leading to this reduction.
METHODS: ENGAGEAF-TIMI 48 was a double-blind, double-dummy comparison of warfarin with 2 regimens
of once-daily edoxaban in 21,105 patientswith atrialﬁbrillation followed for 2.8 years (median). Causes of deaths
in the intention-to-treat populationwere classiﬁed as cardiovascular (including fatal bleeding and ischemic stroke),
malignancy, or noncardiovascular/nonmalignancy by an independent, blinded, clinical endpoint committee.
Deaths also were adjudicated as directly due to bleeding (ie, fatal), or bleeding contributing to death, or neither.
RESULTS: There were 839 total deaths (4.35%/y) in the warfarin arm, compared with 773 (3.99%/y, P ¼
.08) with the higher-dose edoxaban regimen, and 737 (3.80%/y, P ¼ .006) with the lower-dose edoxaban
regimen. No signiﬁcant differences between treatments were observed in (1) any of the 3 most common
causes of cardiovascular death (sudden cardiac, heart failure, ischemic stroke), (2) fatal malignancies, (3)
other noncardiovascular death. There were 124 fatal bleeds, 65 with warfarin, signiﬁcantly fewer with the
higher-dose (n ¼ 35, P ¼ .003) and lower-dose (n ¼ 24, P < .001) edoxaban regimens. There were 101
bleeding events with warfarin that were either fatal or that contributed to death. There were signiﬁcantly
fewer with the higher-dose (n ¼ 59, P ¼ .001) and lower-dose (n ¼ 54, P < .001) edoxaban regimens.
CONCLUSIONS: Fewer total and cardiovascular deaths were observed with edoxaban as compared with
warfarin in the ENGAGE AF-TIMI 48 trial, and this predominantly resulted from the signiﬁcantly lower
rate of major bleeding with edoxaban. Edoxaban reduces mortality both directly (less fatal bleeding) and
indirectly (fewer bleeding-related complications and interruptions in therapy after nonfatal bleeding).
 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).  The American Journal of Medicine (2016)
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0.1016/j.amjmed.2016.02.028and mortality attributed to atrial ﬁbrillation has increased
from 1990 to 2010. This is largely due to aging of the world
population, and adds to a growing and signiﬁcant worldwide
public health burden.1 Although a meta-analysis of 6 trials
involving 2900 patients with nonvalvular atrial ﬁbrillation
randomized to warfarin or placebo demonstrated a 26%
reduction in total mortality with warfarin,2 there was no
signiﬁcant reduction in total mortality with warfarin
compared with antiplatelet therapy in 8 trials involving 3647
patients,2 nor in a subsequent trial of 6706 patientsess article under the CC BY-NC-ND license (http://creativecommons.org/
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ratio [HR] 0.99).3 Residual mortality risk in patients with
atrial ﬁbrillation anticoagulated with warfarin has been
demonstrated4 and may be due to limitations in efﬁcacy or
increased mortality related to side effects of warfarin, or both.
For example, warfarin increases the risk of major hemorrhageCLINICAL SIGNIFICANCE
 An analysis of the causes of death was
performed in a clinical trial of NOAC vs
warfarin in patients with atrial ﬁbrillation.
 Edoxaban reduced mortality primarily by
reducing fatal intracranial bleeding.
 Edoxaban also reduced nonfatal
bleeding, which indirectly may result in
fewer subsequent deaths.relative to no anti-thrombotic or
aspirin. In particular, warfarin can
cause intracranial hemorrhage,
which is frequently fatal or
severely disabling, even despite
rapid reversal5 of the anticoagulant
effect with prothrombin complex
concentrates.6
In contrast, in a meta-analysis
of 4 large, randomized, warfarin-
controlled trials involving 71,683
patients with atrial ﬁbrillation, we
reported that the non-vitamin K
oral anticoagulants (NOACs)
reduced total mortality by 10%Table 1 Classiﬁcation of Death by the Clinical Endpoint
Committee
Categories of causes of death
1. Cardiovascular
a. Fatal bleeding
i. Intracranial hemorrhage
ii. Extracranial bleeding
b. Nonbleeding cardiovascular deaths
i. Ischemic stroke
ii. Systemic arterial embolic event
iii. Congestive heart failure or cardiogenic shock
iv. Directly related to coronary revascularization
v. Dysrhythmia
vi. Pulmonary Embolism
vii. Sudden or unwitnessed deathand did not increase major bleeding as compared with
warfarin.7 In addition, NOACs demonstrated a consistent
and large (approximately 50%) reduction in intracranial
hemorrhage compared with warfarin across these 4 trials,
whereas the observed reduction in thromboembolic events
was modest and variable.7
In the Effective Anticoagulation with Factor Xa Next Gen-
eration in Atrial FibrillationeThrombolysis in Myocardial
Infarction 48 (ENGAGE AF-TIMI 48) trial, the oral factor Xa
inhibitor edoxaban, as compared with well-managed warfarin,
was noninferior for prevention of stroke and systemic embolic
events, while reducing cardiovascular mortality, major
bleeding, and intracranial hemorrhage.8 However, data
regarding the causes of death and the relationship of bleeding to
death with NOACs as compared with warfarin are sparse.
Hence, we analyzed death in the ENGAGEAF-TIMI 48 trial to
explore the factors that contributed to the improved survival
observed with edoxaban.viii. Atherosclerotic vascular disease (excluding coronary
artery disease)
ix. Other
2. Malignancy
3. Other
a. Infection
b. Suicide
c. Accidental/traumatic
d. Hepatobiliary
e. Renal
f. Other
Relationship of death to bleeding
1. Fatal bleeding. Bleeding event led directly to death within 7
days. Cause of death must be either intracranial or extracranial
bleeding.
2. Bleeding contributed to death. Bleeding was part of a causal
chain resulting in death within 30 days.
3. Death unrelated to a bleeding event.METHODS
The ENGAGE AF-TIMI 48 trial was a double-blind, double-
dummy, randomized, controlled trial in 21,105 patients with
atrial ﬁbrillation. Details of the trial design have been pre-
viously described.9 Brieﬂy, patients with atrial ﬁbrillation in
the prior 12 months with a CHADS2 score
10 2 were ran-
domized to warfarin titrated to an international normalized
ratio of 2-3, a higher-dose regimen of edoxaban, or a lower-
dose edoxaban regimen. The doses of edoxaban were 60 mg
and 30 mg once daily in the higher-dose and lower-dose
edoxaban regimen arms, respectively. In both edoxaban
arms the dose was reduced by 50% if patients had any one of
the following at any time during the trial: creatinine clearance
<50 mg/dL, body weight 60 kg, or concomitant use of
verapamil, quinidine, or dronedarone. Major exclusion
criteria were high risk for bleeding, creatinine clearance <30mL/min, need for dual antiplatelet therapy, or acute coronary
syndrome or stroke within 30 days. The primary efﬁcacy
endpoint was the combination of stroke or systemic embolic
events. The principal safety endpoint was major bleeding as
deﬁned by the International Society of Thrombosis and
Haemostasis.11 Patients were followed for a median of 2.8years (interquartile range, 2.4-3.2
years). The protocol and amend-
ments were approved by the ethics
committee at each participating
center. All the patients provided
written, informed consent.
An independent clinical
endpoint committee, blinded to
treatment assignment, adjudicated
all deaths and suspected cerebro-
vascular events, systemic embolic
events, myocardial infarctions,
and bleeding. In the adjudication
of deaths, the clinical endpoint
committee determined the primarycause of death, categorized as shown in Table 1 (see
Appendix, available online, for detailed deﬁnitions). Fatal
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siﬁed as cardiovascular deaths. In addition the clinical
endpoint committee determined whether (1) deaths were
directly caused by bleeding (ie, a fatal bleeding event), (2)
bleeding contributed to, but was not the direct cause of death
within the next 30 days (ie, a death in which a bleeding
event was part of a causal chain of medical events that ul-
timately led to death within 30 days of the bleed, but
bleeding was not directly and/or immediately related to the
subject’s death), and (3) death was not associated with either
of the above (see Appendix, available online, for details).
The present analysis was conducted using the intention-to-
treat principle; it included all patients randomized and
counted all deaths and bleeding events, whether on or off
study drug, that occurred between randomization and the end
of the study drug treatment period. The one exception was the
analysis of consequences of a major bleed while on study
drug, which was conducted in the on-treatment population.
Annualized event rates were calculated as Kaplan-Meier es-
timates. P values <.05 without adjustment for multiple
comparisons were considered nominally signiﬁcant.Table 2 Causes of Death by Treatment Group
Parameter
All Patients
(N ¼ 21,105),
n (%/y)
Warfarin
(n ¼ 70
n (%/y)
All deaths 2349 (4.05) 839 (4.3
Cardiovascular 1668 (2.87) 611 (3.1
Fatal bleeding 124 (0.21) 65 (0.3
Intracranial hemorrhage 98 (0.17) 53 (0.2
Extracranial bleeding 26 (0.04) 12 (0.0
Nonbleeding cardiovascular deaths 1543 (2.66) 546 (2.8
Sudden cardiac death 749 (1.29) 270 (1.4
Heart failure or shock 390 (0.67) 143 (0.7
Ischemic stroke 146 (0.25) 47 (0.2
Dysrhythmia 51 (0.09) 15 (0.0
Atherosclerotic vascular disease 25 (0.04) 8 (0.0
Pulmonary embolism 17 (0.03) 5 (0.0
Directly related to revascularization 12 (0.02) 4 (0.0
Systemic arterial embolism 8 (0.01) 3 (0.0
Other cardiovascular 145 (0.25) 51 (0.2
Malignancy 271 (0.47) 84 (0.4
Lung 72 (0.12) 18 (0.0
Pancreatic 32 (0.06) 5 (0.0
Small or large bowel 22 (0.04) 5 (0.0
All other malignancies 145 (0.25) 56 (0.2
Noncardiovascular/nonmalignancy 410 (0.71) 144 (0.7
Infection 256 (0.44) 92 (0.4
Accidental/traumatic 25 (0.04) 10 (0.0
Renal 21 (0.04) 8 (0.0
All other 108 (0.19) 34 (0.1
Relationship of deaths to bleeding
Bleeding contributed to death 90 (0.16) 36 (0.1
Fatal bleeding or bleeding that
contributed to death
214 (0.37) 101 (0.5
% rates shown are annualized Kaplan-Meier estimates.RESULTS
A total of 2349 deaths occurred, of which 1668 (71.0%)
were cardiovascular, 271 (11.5%) were due to malig-
nancy, and 410 (17.5%) were due other causes (Table 2).
Of these 2349 deaths, 839 deaths (4.35%/y) occurred in
patients randomized to warfarin. Fewer deaths occurred
with the higher-dose edoxaban regimen (773 deaths,
3.99%/y) and with the lower-dose edoxaban regimen (737
deaths, 3.80%/y) as compared with warfarin.
There were a total of 1668 cardiovascular deaths. Of
these, 611 (3.17%/y) occurred in the warfarin group. Both
edoxaban dose regimens signiﬁcantly reduced cardiovas-
cular mortality: higher-dose edoxaban regimen 530 cardio-
vascular deaths, 2.74%/y; lower-dose edoxaban regimen
527 cardiovascular deaths, 2.71%/y. There were no signif-
icant differences among the treatment groups between
deaths due to either malignancy (warfarin 84 [0.44%/y];
higher-dose edoxaban regimen 94 [0.49%/y], lower-dose
edoxaban regimen 93 [0.48%/y]) or other non-
cardiovascular/nonmalignant causes of death, although
numerically fewer occurred with the lower-dose edoxaban36),
HD Edoxaban
(n ¼ 7035),
n (%/y)
P Value,
Warfarin vs
HD Edoxaban
LD Edoxaban
(n ¼ 7034),
n (%/y)
P Value,
Warfarin vs
LD Edoxaban
5) 773 (3.99) .082 737 (3.80) .006
7) 530 (2.74) .013 527 (2.71) .008
3) 35 (0.18) .003 24 (0.12) <.001
7) 30 (0.15) .012 15 (0.07) <.001
6) 5 (0.03) .099 9 (0.05) .50
3) 495 (2.56) .10 502 (2.59) .13
0) 247 (1.28) .29 232 (1.20) .073
4) 129 (0.67) .37 118 (0.61) .10
4) 44 (0.23) .74 55 (0.28) .46
8) 16 (0.08) .87 20 (0.10) .41
4) 5 (0.03) .41 12 (0.06) .39
3) 3 (0.02) .48 9 (0.05) .30
2) 5 (0.03) .75 3 (0.02) .70
2) 0 — 5 (0.03) .50
6) 46 (0.24) .59 48 (0.25) .71
4) 94 (0.49) .47 93 (0.48) .54
9) 29 (0.15) .12 25 (0.13) .31
3) 14 (0.07) .049 13 (0.07) .072
3) 9 (0.05) .30 8 (0.04) .42
9) 42 (0.22) .15 47 (0.24) .35
5) 149 (0.77) .81 117 (0.60) .080
8) 95 (0.49) .86 69 (0.36) .061
5) 10 (0.05) .99 5 (0.03) .20
4) 4 (0.02) .25 9 (0.05) .83
8) 40 (0.21) .49 34 (0.18) .97
9) 24 (0.12) .12 30 (0.15) .44
2) 59 (0.30) .001 54 (0.28) <.001
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regimen 149 [0.77%/y], lower-dose edoxaban regimen 117
[0.60%/y]).Causes of Cardiovascular Death
The 4 most common causes of cardiovascular deaths were
sudden cardiac death (749 [1.29%/y]; 44.9% of the 1668
cardiovascular deaths), heart failure (390 [0.67%/y]; 23.4%
of cardiovascular deaths), ischemic stroke (146 [0.25%/y];
8.8% of cardiovascular deaths), and bleeding (124 [0.21%/
y]; 7.4% of cardiovascular deaths) (Figure 1, Table 2).
There were no differences between the treatment groups
in the ﬁrst 3 subcategories of cardiovascular death
(sudden cardiac death, heart failure, ischemic stroke), but
there was a signiﬁcant excess of fatal bleeding events
with warfarin (n ¼ 65 [0.33%/y]) as compared with both
the higher-dose edoxaban regimen (35 [0.18%/y]; HR
0.54, P ¼ .003 vs warfarin) and the lower-dose edoxaban
regimen (24 [0.12%/y]; HR 0.37, P < .001 vs warfarin).
The rates of fatal bleeding were low and not dissimilar with
the higher-dose edoxaban regimen (0.18%/y) and the
lower-dose edoxaban regimen (0.12%/y, P ¼ .24). The caseFigure 1 Four most common causes of cardiovascular dea
treatment group with a primary cause of death due to sudde
(C), and bleeding (D). There were no signiﬁcant differences
the ﬁrst 3 causes cardiovascular death. There were signiﬁca
compared to each of the edoxaban groups.fatality rates after a major bleeding event were 11.3% with
warfarin, 7.7% with the higher-dose edoxaban regimen
(P ¼ .064), and 8.3% with the lower-dose edoxaban
regimen (P ¼ .20).Deaths Related to Bleeding
Of the 124 (0.21%/y) fatal bleeding events, 98 (0.17%/y,
79% of the fatal bleeds) were due to intracranial hemor-
rhage, even though intracranial hemorrhage accounted for
fewer than 20% (294 of 1592) of the major bleeding events.
This can be explained by the nearly 20-fold greater fatality
rate after intracranial hemorrhage (33%) as compared with
extracranial bleeding (2%; Figure 2). There were 155
(0.97%/y) intracranial hemorrhages in the warfarin group.
Fewer intracranial hemorrhages occurred in the higher-
dose edoxaban regimen group (n ¼ 79 [0.50%/y], P <
.001) and fewer yet in the lower-dose edoxaban regimen
group (n ¼ 60 [0.37%/y], P < .001 vs both the higher-dose
edoxaban regimen and vs warfarin). There was a trend
toward more major extracranial bleeding events in the
warfarin group as compared with the higher-dose edoxaban
regimen group (506 vs 455 [3.16%/y vs 2.87%/y], P ¼ .09),th. Panels (A-D) show the number of patients in each
n cardiac death (A), heart failure (B), ischemic stroke
in the number of deaths between treatment groups for
ntly more fatal hemorrhages in the warfarin group as
Figure 3 Hemorrhages related to death. Fatal hemorrhage
(black) and bleeding events that contributed to death (grey)
are shown by treatment group. P-values shown are compared
to warfarin. All comparisons between higher-dose (HD) and
lower-dose (LD) edoxaban were not signiﬁcant. Intracranial
hemorrhage accounted for 42, 24, and 12 of the fatal bleeding
events in the warfarin, HD edoxaban, and LD edoxaban
groups, respectively. Of the bleeding events that contributed
to death, the majority in each group were extracranial (28, 18,
and 22 in the warfarin, HD edoxaban, and LD edoxaban
groups, respectively).
Figure 2 Fatal and non-fatal bleeding by location. Fatality
rates were far higher for patients with intracranial hemorrhage
(warfarin 32%, high-dose edoxaban 39%, low-dose edoxaban
29%; P ¼ NS for each pairwise comparison) as compared to
extracranial major bleeding (warfarin 4.3%, high-dose edox-
aban 2.2%, low-dose edoxaban 4.2%; P ¼ NS for each
pairwise comparison). *P <.001 vs warfarin. †P ¼ .09 vs
warfarin.
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edoxaban regimen (337 [2.07%/y], P < .001 compared
with either warfarin or the higher-dose edoxaban regimen).
In addition to the signiﬁcant reduction in fatal bleeding
events with edoxaban, there also was a numerical, but statis-
tically nonsigniﬁcant, reduction in bleeding events that were
adjudicated as contributing to death in the edoxaban groups
(warfarin 36 [0.23%/y]; higher-dose edoxaban regimen 24
[0.15%/y], P ¼ .12 higher-dose edoxaban regimen vs
warfarin; lower-dose edoxaban regimen 30 [0.18%/y], P ¼
.44 lower-dose edoxaban regimen vs warfarin). In contrast
with fatal bleeding events, only 17% (16 of 96) of major
bleeding events that contributed to death were due to
intracranial hemorrhage. The total number of bleeding
events that were either fatal or contributed to death was
40%-45% lower (relatively) with edoxaban as compared
with warfarin (Figure 3). In the warfarin group there were
81 (0.42%/y) excess cardiovascular deaths as compared
with the higher-dose edoxaban regimen group, of which
52% (42 of 81) were related to bleeding that was either
fatal or contributed to death. Similarly to the lower-dose
edoxaban regimen, 54% (47 of 84) of the excess cardio-
vascular deaths with warfarin as compared with the lower-
dose edoxaban regimen were related to bleeding.Consequences of Nonfatal Major Bleeding while
on Study Drug
Patients on study drug who experienced a major nonfatal
bleeding event that did not contribute to death had nearly
twice the relative risk of dying before the end of the trialcompared with those who did not have major bleeding
during the trial (7.0% vs 4.1% per year, relative risk unad-
justed 1.9, P < .001). Of the 1080 patients (2.34%/y) on
study drug who survived a major bleed (463 [3.03%/y]
warfarin, 385 [2.53%/y] higher-dose edoxaban regimen, 232
[1.48%/y] lower-dose edoxaban regimen), study drug was
interrupted in 91% for at least 4 days, with similar rates
(91% warfarin, 90% higher-dose edoxaban regimen, 91%
lower-dose edoxaban regimen) across the 3 treatment
groups. Of these 979 who interrupted study drug, 53% were
rechallenged with study drug, and 37% received open-label
anticoagulant, whereas 10% did not receive any further
anticoagulant (neither study drug nor open-label anticoag-
ulant) for the remainder of the trial.
Patients who survived a major bleed but interrupted anti-
coagulation for 4 days experienced high rates of subsequent
major adverse cardiac events (7.9% annualized rate of major
adverse cardiac events, deﬁned as cardiovascular death,
myocardial infarction, stroke, or systemic embolic events) and
of all-cause death (7.1%/y), regardless of randomized treat-
ment. In the warfarin group, 423 patients (2.72%/y) inter-
rupted anticoagulation after a nonfatal major bleed that did not
contribute to death. Because edoxaban reducedmajor bleeding
as compared with warfarin, the corresponding number of pa-
tients who interrupted study drug after major bleeding were
fewer with the higher-dose edoxaban regimen (345 [2.23%/y],
P ¼ .004 vs warfarin) and fewer yet with the lower-dose
edoxaban regimen (211 [1.32%/y], P < .001 vs warfarin and
vs higher-dose edoxaban regimen). After interruption of study
drug due to a nonfatal major bleeding event, there were
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edoxaban (higher-dose edoxaban regimen 64, P ¼ .18 vs
warfarin; lower-dose edoxaban regimen 42, P ¼ .001 for
lower-dose edoxaban regimen vs warfarin). Similarly, there
were more major adverse cardiac events after study drug
interruption due to a nonfatal major bleed with warfarin (n ¼
111) as compared with the higher-dose edoxaban regimen (66,
P ¼ .001 vs warfarin) and the lower-dose edoxaban regimen
(58, P < .001 vs warfarin).DISCUSSION
In this analysis of causes of total mortality and the rela-
tionship between bleeding and causes of death in the
ENGAGE AF-TIMI 48 trial, we found that more than half
of the reduction in all-cause deaths with edoxaban as
compared with warfarin was directly attributable to fewer
fatal bleeding events and nonfatal major bleeding that
contributed to a death within 30 days. There were no dif-
ferences between edoxaban and warfarin in deaths due to
noncardiovascular causes, nor for any of the 3 most com-
mon cardiovascular causes of death (sudden cardiac death,
heart failure, ischemic stroke). However, warfarin was
associated with approximately twice the risk of fatal
bleeding as compared with edoxaban. Because edoxaban
(like other NOACs) reduces intracranial hemorrhage by
approximately 50% relative to warfarin,7 and intracranial
hemorrhage carries a high fatality rate12 (1 in 3 in this
study), the single greatest factor accounting for the lower
total mortality with edoxaban was a reduction in fatal
intracranial hemorrhage (by 43% and 72% with the higher-
dose edoxaban regimen and the lower-dose edoxaban
regimen, respectively, compared with warfarin).
In addition to a reduction in fatal bleeding events with
edoxaban, there also were fewer nonfatal major bleeding
events in patients treated with edoxaban. This latter ﬁnding
also may have contributed to the reduction in total mortality
with edoxaban in 2 ways. First, patients who initially sur-
vive a major bleeding event may subsequently develop
another medical complication that ultimately proves fatal,
for example an event that is (1) a direct consequence of the
bleed (eg, hypovolemic shock leading to myocardial or
cerebral infarction), (2) related to management of the
bleeding event (eg, transfusion- or procedure-related
complication), or (3) due to an in-hospital complication
(eg, nosocomial infection). Second, patients who survive a
major bleed often interrupt anticoagulation for several days
(91% in this study), and interruptions in anticoagulation
place patients with atrial ﬁbrillation at an increase risk of
thromboembolic events and death.1 In fact, even brief in-
terruptions of anticoagulation for 5 days have been asso-
ciated with increased risk.13,14
Our ﬁnding that the majority of deaths among patients
with atrial ﬁbrillation treated with a NOAC or well-
managed warfarin are cardiovascular in nature is consis-
tent with those reported by the RE-LY investigators.15 The
numerically greater proportion of cardiovascular deaths inENGAGE AF-TIMI 48 (71%) as compared with RE-LY
(61%) may be attributable to the greater burden of risk
factors in the ENGAGE AF-TIMI 48 trial (patients with
CHADS2 score 3-6 represented 53% of the ENGAGE
AF-TIMI 488 and 32% of the RE-LY16 trial populations). In
both trials there were trends favoring the NOACs over
warfarin, with relative reductions in total mortality of 8%-
13%. Although there were no differences between the
NOACs and warfarin in the most common forms of car-
diovascular death (sudden cardiac death, heart failure) in
either trial, a signiﬁcant reduction in vascular deaths
(including stroke, peripheral or pulmonary embolism, and
bleeding) was observed with dabigatran as compared with
warfarin in RE-LY.15 In the present analysis, we extended
these ﬁndings to show more speciﬁcally that the major
explanation for lower mortality with edoxaban was related
to the large reductions in bleeding events that were either
fatal or contributed to death within 30 days. Both apixaban
and rivaroxaban reduce intracranial hemorrhage by
approximately 50% compared with warfarin; however,
similar detailed analyses of the causes of death in the large
phase 3 trials comparing these 2 factor Xa inhibitors with
warfarin have not been published.17-19
We believe that our ﬁndings provide a strong rationale
to consider a NOAC rather than warfarin to reduce
bleeding and death, while preserving protection from
thromboembolism in patients with atrial ﬁbrillation at
moderate to high risk for stroke. Our results provide
further support to the recommendations from the European
Society of Cardiology20 and the Japanese Circulation So-
ciety21 favoring NOACs over vitamin K antagonists for
most patients with atrial ﬁbrillation and 2 or more risk
factors for stroke. With the anticipated availability in the
near future of antidotes to factor Xa and thrombin in-
hibitors,22 the safety advantage of the NOACs over
vitamin K antagonists should be enhanced even further,
potentially extending the net clinical beneﬁt with NOACs
to patients with even lower risk of stroke.23,24
We acknowledge some limitations. This analysis was
limited to patients who met entry criteria for and agreed to
participate in a randomized clinical trial, and the ﬁndings
may differ in a general population. Second, attributing a
single cause of death is challenging despite use of pro-
spective deﬁnitions because multiple factors may contribute
to death, source data are not always available (eg, for
deaths that occur at non-study institutions), and autopsies
are infrequently performed. However, because adjudicators
of death were unaware of treatment assignment, the like-
lihood of introducing substantial bias is minimized. Clas-
siﬁcation of bleeding deaths as cardiovascular was arbitrary
but was prespeciﬁed in the trial protocol. Nonetheless, the
validity of our results still stand if bleeding deaths were
considered in a separate category. This analysis does not
address the question of how much bleeding should be
tolerated to prevent a thromboembolic event nor which
dose regimen of edoxaban should be selected for individual
patients.
856 The American Journal of Medicine, Vol 129, No 8, August 2016Strengths of our analysis include the independent adju-
dication of causes of death by an expert committee blinded
to treatment assignment, using a detailed prospectively
designed charter. The dataset also represents the largest
(21,105 patients) and longest (2.8 years median) follow-up
with the greatest number of total deaths (n ¼ 2349) from
a randomized trial in patients with atrial ﬁbrillation con-
ducted to date. Follow-up for vital status was complete for
all except 1 patient, and complete information for key
clinical endpoints was available in 99.5% of the total 56,346
patient-years of potential follow-up.8 The median time in
therapeutic range was 68.4% (interquartile range, 56.5%,
77.4%) among the patients treated with warfarin, which is
higher than that reported in prior NOAC versus warfarin
trials16-18 (range, 58%-66%) and in a recent US assessment
involving 138,319 Americans with atrial ﬁbrillation (median
57.5%).25CONCLUSIONS
In patients with atrial ﬁbrillation at moderate to high risk of
stroke randomized to edoxaban versus warfarin in the
ENGAGE AF-TIMI 48 trial, the signiﬁcant reduction in
cardiovascular mortality observed with edoxaban was
mediated primarily by lower rates of bleeding that were
either fatal or contributed to death in the subsequent 30
days.
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(CEC) CLASSIFICATION OF DEATH
Death will be classiﬁed as Cardiovascular, Malignancy, or
Noncardiovascular/Nonmalignancy. The cause of death is
determined by the principal condition that caused the death,
not the immediate mode of death. All deaths will be
assumed to be cardiovascular in nature unless a malignant or
a noncardiovascular cause can be clearly shown.
Cardiovascular death is deﬁned as death due to docu-
mented cardiovascular cause, including deaths due to
bleeding. Causes of cardiovascular deaths include, but are
not limited to, deaths resulting from atherosclerotic coronary
heart disease (acute myocardial infarction, sudden cardiac
death, non-sudden death with gradually worsening cardiac
symptoms, unwitnessed death without clear alternate cause,
procedural death related to cardiac surgery, or coronary
angiography), atherosclerotic vascular disease (cerebrovas-
cular disease including stroke and hemorrhage, aortic,
mesenteric, renovascular, peripheral arterial disease, or
complication of a noncoronary vascular procedure), other
cardiovascular (pulmonary embolism, endocarditis,
congestive heart failure, valvular heart disease, arrhythmia),
and deaths due to bleeding.
Deaths due to malignancy will include deaths that are
directly a consequence of a malignancy, such as a brain
tumor that causes herniation, coma, and respiratory arrest.
Deaths due to malignancy will be further subclassiﬁed by
organ system and timing of diagnosis (before vs after
randomization).
Examples of noncardiovascular/nonmalignancy deaths
include those caused primarily by infection, pulmonary,
gastrointestinal, accidental, renal, trauma, or non-
cardiovascular organ system failure.
For all deaths, the relationship of the death to bleeding
and malignancy will be adjudicated as follows.RELATIONSHIP TO BLEEDING (CATEGORIES ARE
MUTUALLY EXCLUSIVE)
1. Fatal bleeding: death in which a bleeding event
directly led to death within 7 days. Examples of fatal
bleeding events are an intracranial hemorrhage that led
to herniation of the brain and death within 24 hours,
and a massive gastrointestinal hemorrhage that results
in shock, hemodynamic collapse, and death. If a
bleeding event is considered fatal, then the cause of
death must be either intracranial or non-intracranial
bleeding.
2. Bleeding contributed to death: a death in which a
bleeding event was part of a causal chain of medical
events that ultimately led to death within 30 days of the
bleed, but bleeding was not directly and/or immediately
related to subject’s death. An example of bleeding
contributing to death is a large retroperitoneal bleed
that leads to surgical evacuation, development of asubsequent abscess in the area of bleeding that leads to
sepsis, multiorgan failure, and death 10 days after the
onset of bleeding. If bleeding has contributed to death
(but the bleeding was not categorized as “fatal”), then the
cause of death must be recorded as something other than
intracranial/non-intracranial bleeding.
3. Deaths unrelated to a bleeding event: the cause of death
was unrelated to bleeding, either because there was no
clinical signiﬁcant bleeding in the month before death or
the bleeding event did not contribute to the subject’s
death. An example of a death unrelated to bleeding is an
episode of guaiac-positive stools in a patient who dies of
postobstructive pneumonia due to lung cancer. In these
cases, the cause of death cannot be intracranial/non-
intracranial bleeding.RELATIONSHIP TO MALIGNANCY
1. Death directly related to malignancy: death in which the
mode of death can be attributed to the direct effects of a
malignancy. In such cases, the cause of death adjudicated
by the CEC must be malignancy.
2. Death due to a consequence related to malignancy: this
would include deaths due to other processes (eg, infec-
tion in a patient who becomes septic and neutropenic due
to acute leukemia) that are a known complication of the
malignancy. The underlying malignancy should be on the
causal pathway leading to death but not the immediate
cause of death. In such cases the cause of death adjudi-
cated by the CEC cannot be malignancy, but instead
should be the other process (eg, infection).
3. Death not related to a malignancy: either no malignancy
has been diagnosed or the malignancy that is present was
not related to the cause of death. The cause of death must
be something other than malignancy.SUDDEN CARDIOVASCULAR DEATH
Sudden CV death is deﬁned as a sudden, unexpected death
that was either:
1. Witnessed, occurring within 60 minutes from the onset of
new symptoms, in the absence of a clear cause other than
cardiovascular; or
2. Unwitnessed, within 24 hours of being observed alive, in
the absence of pre-existing progressive circulatory failure
or other non-cardiovascular causes of death.NON-SUDDEN CARDIOVASCULAR DEATH
This category refers to a patient who had symptoms of a
cardiovascular nature and had gradual deterioration before
death. It includes all patients with CV death who do not
meet criteria for sudden death or unwitnessed CV death.
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Death that occurred unexpectedly, without patient being
seen within 24 hours, and for which no known other major
causes of death are identiﬁed.ILLUSTRATIVE EXAMPLES OF CAUSE OF DEATH
Cardiovascular Death
 A subject found dead at home without known major
noncardiovascular illness for which death was expected
 A subject with renal failure on hemodialysis who dies
after a recurrent myocardial infarction
 A subject who dies after aortic dissection
 A subject who dies of complications of endocarditis
 A subject who dies of complications related to coronary
artery bypass surgery or percutaneous coronary
intervention
 A subject who dies within 24 hours since the onset of
neurologic symptoms compatible with a stroke
 A subject who dies suddenly and autopsy shows either a
cerebral infarction or a cerebral hematoma (note: the
latter event would also be classiﬁed as a fatal bleeding
event) A subject who dies of progressive hypotension in the
setting of a severe gastrointestinal hemorrhage (note: this
event would also be classiﬁed as a fatal bleed)
Malignancy Death
 A subject with an unresectable tracheal carcinoma that
causes airway compromise and respiratory arrest
 A subject with metastatic breast cancer that causes a
recurrent malignant pericardial effusion and pericardial
tamponade
Noncardiovascular/Nonmalignancy Death
 A subject with progressive interstitial pulmonary ﬁbrosis
with home hospice care who is found dead at home
 A subject with severe pneumonia and hypoxia who has a
bradycardic arrest
 A subject who dies of multiple trauma in a motor vehicle
accident
 A subject with stage IV prostate cancer with widespread
metastases who dies of hepatic encephalopathy (note:
this event would also be classiﬁed as a death due to a
consequence of a malignancy, hepatic failure due to
metastatic disease)
